Fate Therapeutics Inc expected to post a loss of 62 cents a share - Earnings Preview

Fate Therapeutics

02/05/2023 03:03

* Fate Therapeutics Inc  FATE.OQ   FATE.O  is expected
to show a
rise in quarterly revenue when it reports  results on May 3. 
    * The San Diego California-based  company is expected to
report  a
92.8% increase in revenue to $35.503 million from $18.41 million
a year ago, according to the mean estimate from 19 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Fate Therapeutics
Inc is
for a loss of 62 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 14
"hold" and 2 "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 0.1%
in the last three months. ​
    * Wall Street's median 12-month price target for Fate
Therapeutics
Inc is $7​, above​ its last closing price of $6.36. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -0.85       -0.86      -0.58     Beat    32.7
 Sep. 30 2022  -0.87       -0.89      -0.86     Beat    3.7
 Jun. 30 2022  -0.81       -0.83      -0.79     Beat    4.4​
 Mar. 31 2022  -0.77       -0.77      -0.68     Beat    11.1
 ​​Dec.        -0.65       -0.67      -0.72     Missed  -8
 31 2021                                                
 Sep. 30 2021  -0.59       -0.58      -0.45     Beat    22.6​
 Jun. 30 2021  -0.54       -0.53      -0.58     Missed  -10
 Mar. 31 2021  -0.45       -0.43      -0.48     Missed  -10.9
 This summary was machine generated May 2 at 02:03 GMT.  All
figures in US dollars  unless otherwise stated